Prognosis
An AI Firm Wants to Predict Costly Pharma Flops
- Innoplexus works with fund, consultants on pipeline prophesies
- Biogen’s Alzheimer tumble shows perils of drug-trial guesswork
This article is for subscribers only.
Want more news about the future of health care? Sign up here for Bloomberg’s Prognosis newsletter to get great stories delivered to your inbox every Thursday.
Before Biogen Inc.’s experimental Alzheimer’s disease drug failed in a trial last month, analysts surveyed by Bloomberg estimated annual sales of about $3.7 billion by 2023. A German artificial-intelligence firm had come to a different conclusion.